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Abstract
This evidence review addresses whether type 2 diabetes genomic risk panels improve health 
outcomes (e.g., reduce rates of developing type 2 diabetes) in low- or high-risk adults; two clinical 
scenarios promulgated by commercial companies offering such testing. Evidence for the analytic 
validity of available genomic profiles was inadequate. Clinical validity ranged from inadequate to 
convincing for 30 variants identified on five type 2 diabetes genomic panels and by genome-wide 
association studies. Eight common variants were identified for general population use; evidence 
credibility based on published criteria was strong for two variants, moderate for two variants, and 
weak for four variants. TCF7L2 had the largest per-allele odds ratio of 1.39 (95% confidence 
interval 1.33–1.46). Models combining the best four, best eight, and all 30 variants used summary 
effect sizes, reported genotype frequencies, and assumed independent effects. Areas under the 
curve were 0.547, 0.551, and 0.570, respectively. In high-risk populations, per-allele odds ratios 
for TCF7L2 alone were similar to those of the general population. TCF7L2, in combination with 
other variants, yielded minimal improvement in risk reclassification. Evidence on TCF7L2 clinical 
validity was adequate. Three studies addressed the clinical utility of intervention effectiveness, 
stratified by TCF7L2 genotype; none found significant interactions. Clinical utility evidence was 
inadequate. In addition to analytic validity and clinical utility knowledge gaps, additional gaps 
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were identified regarding how to inform, produce, and evaluate models combining multiple 
variants.
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INTRODUCTION
Diabetes mellitus refers to a group of metabolic diseases that are characterized by chronic 
elevations in plasma glucose. Up to 95% of all diabetes is considered type 2 diabetes (T2D), 
which was previously known as “adult-onset” or “non–insulin-dependent diabetes.” The 
metabolic mechanisms for T2D include insulin resistance, impaired insulin secretion, and 
increased hepatic glucose production. Complications can include nephropathy, neuropathy, 
retinopathy, periodontal disease, and accelerated development of cardiovascular disease. 
Approximately 1.9 million people aged 20 years or older were newly diagnosed with 
diabetes in 2010 in the United States.1 T2D is becoming more common in the United States 
and throughout many regions of the world. The T2D prevalence in youths aged 10 years and 
older is 8.5 per 100,000, whereas the prevalence is 0.4 per 100,000 in youths younger than 
10 years.1 The prevalence is even higher among adults aged 65 years and older, with 10.9 
million, or 26.9%, of all people in this age group being affected.1 However, the Centers for 
Disease Control and Prevention estimates as many as 27% of individuals with T2D are 
undiagnosed. Factors such as an aging population and rising rates of obesity are expected to 
further increase the prevalence.
The prevalence of T2D varies by race and ethnicity, with higher rates among African 
Americans (11.4%), Hispanic/Latino Americans (8.2%), Native Americans (8.2% among 
Alaska Natives, 27.8% among certain Native American tribes from the Southwest, and up to 
50% among Pima Indians and some Asian-American and Pacific Islander groups). 
Randomized trials have demonstrated that changing lifestyle factors (e.g., weight loss, 
improved diet, and increased physical activity) can help prevent or delay the development of 
diabetes.2–9
A family history of diabetes is a major risk factor for the disease and is often included in 
tools designed to quantify the risk of diabetes,10 with odds ratios (ORs) of two to six, if one 
or more first-degree relatives have been diagnosed with T2D.11 A long-term study reported 
that the cumulative prevalence of T2D at 80 years of age is approximately 3.5 times higher 
(38% vs. 11%) for individuals with a first-degree relative diagnosed with T2D as compared 
with individuals without any relatives diagnosed with T2D.12
Several commercial and noncommercial entities are now offering diabetes risk testing alone 
or as a part of a panel involving risk profiling for chronic diseases. If these gene panels were 
to demonstrate the capacity of identify a subgroup with important increases in the risk of 
developing diabetes, it might be possible to implement targeted prevention strategies that 
might be too invasive or too resource intensive to be offered to a general population. Such 
testing and targeted interventions have the potential to reduce the burden of disease.
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The Evaluation of Genomic Applications in Practice and Prevention Working Group (EWG) 
was established in 2005 to support the development of a systematic process for assessing the 
available evidence for rapidly emerging genetic tests for clinical practice. This independent, 
multidisciplinary panel selected this topic to commission an evidence report to review 
validity and utility and highlight critical knowledge gaps, in order to provide guidance on 
appropriate use of the available genetic tests in specific clinical scenarios. T2D risk panels 
were selected for evaluation by Genomic Applications in Practice and Prevention because of 
the prevalence and burden of T2D. Testing is offered through both clinical and direct-to-
consumer models, each with unique considerations, and for two clinical scenarios. 
Estimating the risk of T2D on the basis of variants in multiple genes, individually and in 
combination, challenges risk assessment and Genomic Applications in Practice and 
Prevention evidence review methods. The analytic validity (technical test performance), 
clinical validity (the strength of association that determines the test’s ability to accurately 
and reliably identify or predict the disorder of interest), and clinical utility (balance of 
benefits and harms when the test is used to influence patient management) are systematically 
reviewed.13
The EWG chose to examine test performance in two separate clinical scenarios that have 
been promulgated by those offering clinical testing. The first was a claim that a gene panel 
consisting of multiple markers could identify adults from the general population who would 
be at high risk of developing T2D. These individuals could then be offered targeted 
interventions to reduce the likelihood of developing T2D in the future. The second scenario 
involved testing adults who had already been identified as being at high risk of developing 
T2D in the near future. At the time the review was commissioned, claims for this scenario 
involve testing for only one gene (TCF7L2). The aim of the review is not to provide a 
comprehensive review of all potential genomic markers for T2D. According to Phenopedia 
(www.cdc.gov/genomics/hugenet/hugenavigator.htm), there are 3,267 genes already studied 
in relation to T2D, with 208 meta-analyses and 106 genome-wide association (GWA) 
studies, with several hundred publications added per year. Rather, this review focuses on 
what T2D panels are clinically available and determine through an overview of additional 
markers whether it is reasonable to assume that important advances in the clinical validity of 
these panels are expected.
METHODS
Overview
The targeted evidence-based review process used to identify, review, analyze, evaluate, and 
summarize the evidence is briefly presented here, but an in-depth presentation of EWG 
methods has been published.13 A consultant from Women & Infants Hospital’s Department 
of Pathology and Laboratory Medicine (G.E.P.) with experience in evidence review of 
genetic tests was contracted by the Office of Public Health Genomics at the Centers for 
Disease Control and Prevention to assist in the targeted review by the three members of that 
office (M.P.D., S.M., and M.M.). Guidance was provided by a technical expert panel, whose 
members are listed in the Acknowledgments section.
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An analytic framework and key questions for two clinical scenarios (Table 1, Figure 1) were 
developed by the EWG with support from Genomic Applications in Practice and Prevention 
staff and refined through discussion at technical expert panel calls and EWG meetings. The 
review not only focuses on clinical validity but also addresses the limited information 
available on the platforms used for testing (analytic validity) and potential evidence for 
clinical utility both in clinical practice and in direct-to-consumer settings.
Standard methods were used, including systematic searches of published literature, limited 
identification of gray literature, use of inclusion/exclusion criteria, abstraction of data, meta-
analysis, assessment of individual study quality, and grading of overall strength of 
evidence.13 Details on these methods as applied to this study are provided in the relevant 
sections below. In reviewing the available evidence, questions from the ACCE (Analytic 
validity, Clinical validity, Clinical utility, and Ethical, legal and social implications) review 
framework were often used to identify and organize information.14
Analytic validity
Targeted PubMed15 searches were performed for the alleles/single-nucleotide 
polymorphisms (SNPs) and specific terms with the expectation of identifying published 
papers reporting on the analytic validity of methods specific to these genomic panels. For 
example, the PubMed search for TCF7L2 was as follows: “TCF7L2 OR TCF7L2 
genotyping” AND “analytic validity OR clinical test.” The same search was performed for 
each of the variants listed in Table 2. Gray literature searches (e.g., company and genetic 
testing websites) were also conducted to collect any available information on laboratories 
offering testing for these markers and the methodologies used.
Clinical validity
To increase efficiency, the review process was limited in the following ways: (i) inclusion of 
only published studies that reported T2D as the primary outcome, (ii) restriction of 
examined genes/polymorphisms to those included in T2D panels available in the United 
States in August 2010, and (iii) use of existing meta-analyses, when possible. Existing meta-
analyses were considered acceptable if they were published in the past several years, 
reported summary effect size, included a formal analysis of heterogeneity, and examined the 
potential for publication bias. Searches of the published literature were conducted using 
HuGE Navigator v2.0.16,17 We have shown in a previous targeted review that this is a more 
specific search strategy that maintains sensitivity for identifying appropriate articles for 
review equivalent to PubMed.18 Specific search strategies for each gene are contained in 
Supplementary Appendix A online. Reference lists of retrieved publications were also 
examined to identify relevant studies. Searches began in August 2010 and were performed 
through November 2010. The search was rerun in April 2012 to identify recent publications. 
One investigator (M.M., M.P.D, or S.M.) had primary responsibility of study selection and 
information extraction for each gene, and results were reviewed by another (usually G.E.P.). 
Discrepancies were resolved by discussion.
To be included, the study (or meta-analysis) needed to be in English and include information 
about individuals of European descent (Caucasian). Articles with only non-European 
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populations were excluded because the tests included in the review were for European 
descent populations. The primary outcome of T2D was defined in multiple ways: (i) fasting 
blood glucose level >126 mg/dl on two occasions, (ii) hemoglobin A1c test level of ≥6.5%, 
and (iii) oral glucose tolerance test level >200 mg/dl after 2 h.19 In clinical scenario 1 
(testing in the general population), the presence or absence of T2D risk factors is not a 
consideration. In clinical scenario 2 (testing in high-risk individuals), each person 
considered for testing must also have traditional risk factor(s) (e.g., obesity, impaired 
glucose tolerance). For clinical scenario 1, sufficient data needed to be present to express the 
effect size as an OR with confidence interval (CI). For clinical scenario 2, sufficient data to 
quantify the follow-up time period were required.
Summary ORs and corresponding 95% CIs were derived using a random effects model, 
either from the original source (published meta-analysis), from a reanalysis of the reported 
data, or from a new literature summary (Comprehensive Meta-Analysis, Version 2; 
Englewood, NJ). The preferred summary effect size was an allele-specific OR, with the 
largest genotypic group used as the referent. When possible, heterogeneity was expressed 
using the I2 statistic20 for ease of interpretation and comparison between studies.
The genes included on the genomic panel for clinical scenario 1 were addressed in three 
tiers. Tier 1 included the four markers found on an early 2010 Google search for “Type 2 
Diabetes Risk Tests.” That search identified only four gene panels (TCF7L2, CDKAL1, 
CDKN2A/B, and PPARG). These four markers were included on all T2D panels reviewed; a 
full analysis was planned for these genes. Tier 2 included four more genes (HHEX, 
SLC30A8, KCNJ11, and WFS1) that were found to have been added to most panels; these 
were also subject to complete review. Tier 3 included all remaining gene markers that were 
identified on only one panel or that were identified as part of an overview of GWA studies. 
These were subjected to a less stringent analysis that involved calculating a summary OR 
based only on GWA studies of T2D.
An evaluation guideline to assess the cumulative evidence provided by genetic association 
studies was published in 2008.21 These “Venice criteria” focused on amount of evidence, 
replication of evidence, and protection from bias. Each criterion is assigned a grade of “A,” 
“B,” or “C.” The amount of evidence, for example, would receive an “A” if >1,000 cases/
controls with the least common genotype were included in computing the effect size 
estimate, “B” if there were 100–1,000 study subjects, and “C” if <100. As suggested in this 
grading system,21 epidemiological evidence for a significant association was rated as 
“strong” if the meta-analysis received three A grades, “moderate” if it received any B grade 
but not any C grade, and “weak” if it received a C grade in any of the three criteria. These 
criteria may not be as relevant for assessing evidence from large GWA studies.
For clinical scenario 1, it was considered unlikely that any data set would be able to 
adequately assess the independence of multiple gene disease associations. As a way to set a 
reasonable upper limit, we chose a multiplicative model that assumes each gene marker to 
be an independent predictor of T2D risk.18 Before multiplying a set of ORs, we adjusted 
them so that there was no overall impact on the population prevalence of T2D risk.22
Palomaki et al. Page 5













The methods used to estimate the overall clinical validity of genomic panels using multiple 
markers has been described previously.18 Briefly, a Monte Carlo simulation23 was used to 
estimate the distribution of genotypes in individuals with and without T2D using the 
cumulative allele-specific OR and the risk allele frequency derived from the literature 
review. Genomic markers were assumed to be independent, and each OR was multiplied to 
compute the cumulative OR for each individual modeled. Before modeling, the ORs were 
adjusted such that there was no effect on the prevalence of the disorder. The resulting 
distributions of cumulative ORs were divided into 20 equal categories (on the logarithmic 
scale) from 0.1 to 10.
The common name for each gene included in a commercially available T2D test was 
searched using the Genopedia option in the HUGE Navigator24 for type 2 diabetes to 
identify meta-analysis of published GWA study findings. If a meta-analysis of GWA studies 
was not available, the original GWA studies reporting the association for that gene’s 
association with T2D in people of European descent was used. Additional genes not 
included in commercially available tests were included when results from GWA studies 
meta-analysis or original GWA studies were available. A table listing all of the SNPs in 
commercially available tests and select GWA studies with variants identified as of August 
2011 was populated with the risk allele, allele frequency, measure of association (OR), and 
estimates of variance (95% CI). Since August 2011, nine additional variants (CENTD2, 1.14 
(1.11–1.18); HMGA2, 1.08 (1.04–1.12); IRS1 1.10 (1.08–1.13); KLF14, 1.06 (1.03–1.09); 
PRC1, 1.06 (1.03–1.08); PROX1, 1.07 (1.05–1.09); TP53INP1, 1.05 (1.03–1.08); ZBED3, 
1.07 (1.04–1.10); and ZFAND6*, 1.05 (1.03–1.08)) identified from the Voight and Dupuis 
GWA studies were added to the deCodeMe test, and two additional previously identified 
variants (MTNR1B and KCNQ1) were added to the 23andMe test.25,26 Overall, the ORs 
ranged from 1.06 to 1.14 for these nine new variants. The addition of these variants to 
existing test panels and modeling would not change the final outcomes. Because the aim was 
more “horizon scanning” than definitively determining the ORs and allele frequency, we 
chose not to perform an exhaustive review of these later markers.
Clinical utility
A full systematic review of the entire literature on the clinical utility of any genomic 
markers/panels was not undertaken. Rather, targeted PubMed searches18 were focused on 
identifying studies reporting on the potential clinical utility only of genetic testing for T2D 
among the general population and among the defined high-risk population for each clinical 
scenario. Specific PubMed search strings were “type 2 diabetes” AND “gene intervention 
OR gene interaction” AND “utility OR outcomes.” Studies that reported gene intervention 
or interaction among the genetic variants that reported clinical outcomes (e.g., increase or 
decrease of T2D development, increase/ decrease in T2D mortality, change in fasting blood 
glucose) for T2D included in this report are listed in Supplementary Appendix B online. In 
general, intermediate outcomes without validation to a clinical outcome (such as reduction 
in weight) were not included. The exception was the validated clinical outcome of reducing 
the intermediate measure of plasma glucose levels.27,28 Data from the final list of included 
studies were abstracted into evidence tables including genetic variant, outcome measured, 
population, and treatment effects stratified by genetic variant and intervention. Articles from 
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the clinical validity review were also reviewed for information related to clinical utility. This 
review was also updated in April 2012.
RESULTS
Genomic panels for T2D risk
The existing genomic panels for T2D risk prediction that are available in the United States 
were identified as part of a routine horizon scanning process by staff of the Office of Public 
Health Genomics.29 Such tests were available through a health-care provider (Baylor) or 
through a direct-to-consumer offer (23andMe, DeCodeMe, DeCode T2, and Navigenics). 
Table 2 lists the five genomic test panels that met these criteria along with the 27 genetic 
markers included on those panels and eight additional markers found in GWA studies 
through additional horizon scanning. The deCODE T2 (four markers) and the deCODE Me 
(21 markers originally, currently 30) tests are offered by deCODE genetics (Reykjavik, 
Iceland). 23andMe (9 originally, currently 11; Mountain View, CA), Navigenics (Foster 
City, CA), and Baylor College of Medicine (Houston, TX) offer interpretations based on 9, 
18, and 7 genomic markers, respectively. Only the deCODE T2 and Baylor tests focus solely 
on T2D. The other tests are part of a larger SNP array for which an analysis of T2D markers 
is included as part of interpretations for multiple complex disorders (e.g., cardiovascular 
disease). The top four rows of Table 2 show markers that are included in nearly all panels 
and have been offered for several years. The next four rows show genes that have been more 
recently included on most of the identified genomic panels (tier 2). In the next 27 rows are 
the less commonly included markers used in genomic panels (tier 3); 14 of them are 
included on only one genomic panel. For completeness, the bottom of the table includes 
eight additional markers identified through a single summary of three GWA studies of 
T2D.30–32 Several existing panels have increased in size over time, and these are also 
potential candidates for inclusion.
Analytic validity
PubMed searches for each of the genes on the genomic panels (e.g., as “TCF7L2” or 
“TCF7L2 genotyping”) and specific terms (e.g., “analytic validity” and “clinical test”) 
identified no articles that provided relevant data on analytic validity. The testing methods 
used in the research studies reviewed for clinical validity were not considered relevant 
because they did not include method comparisons and were often not representative of 
clinical practice. Most importantly, websites from the five companies offering gene/genomic 
panels related to T2D were reviewed for information related to analytic validity, but no such 
information was found.
No US laboratories were found in the GeneTests33 database offering testing for any of the 
genes found in the genomic panels in the general population for T2D (clinical scenario 1) or 
for TCF7L2 and T2D in the high-risk population (clinical scenario 2). In contrast, these 
panels are part of a whole-exome/whole-genome scan that is interpreted for prediction/risk 
for several diseases. Two panels (DeCODE T2 and Baylor College of Medicine)34 are 
specifically for T2D risk prediction in the general population. No external proficiency 
testing program (e.g., American College of Medical Genetics/College of American 
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Pathology) or formal interlaboratory comparison program was found for these panels or for 
the genes in these panels.35 Publications providing relevant information on the analytic 
validity of testing for these genes were not identified.
Relevant genotyping methodologies
The literature on allele/SNP genotyping described laboratory-developed tests and a large 
number of commercially available reagents and platforms.36,37 In general, genotyping 
methods have involved discrimination of alleles by primer extension, hybridization, ligation 
or enzymatic cleavage, and detection using fluorescence, mass, gel electrophoresis, or 
chemiluminescence.36 Mistaken alleles, allelic dropout (i.e., amplification of only one of 
two alleles in a heterozygous individual), and other genotyping errors can result from a 
number of causes. These include interaction with flanking DNA sequences, low quality/
quantity of DNA in samples, laboratory problems related to reagents/protocols/equipment, 
and human error (e.g., sample mislabeling or contamination and data entry and interpretation 
mistakes). Questions remain about causes and rates of genotyping errors in newer 
technologies (e.g., multiplex assays, chips, and SNP arrays) used in routine clinical practice 
and their potential impact on patient results.38
Clinical validity
Literature searching—We used HuGE Navigator to search for gene/disease association 
studies for each gene of interest found in Table 2. The results of literature searches and 
review can be found in detail for each gene in Supplementary Appendix A online. No new 
publications were identified from the most recent search.
Clinical scenario 1: association of genomic markers with T2D—Table 2 provides 
a summary of evidence for the association of individual genes/variants and T2D. The gene 
abbreviation, genomic panel, and the SNP’s identifying RefSNP (rs) number are provided, 
along with the “risk” allele frequency. It should be noted that the risk allele used in all of 
these panels is not necessarily causative. Rather, it is most likely a marker, which may help 
to explain the relatively low ORs obtained. Where determined, the credibility of the 
evidence (Venice criteria) and associated grades are provided. In the last column, the OR 
and 95% CI are shown. For example, the first row summarizes the information for the 
TCF7L2 gene SNP rs7903146. The risk allele (T) frequency is 29% (i.e., 8% of the 
population will carry two copies (TT), 42% one copy (CT), and the remaining 50% no 
copies of the risk allele (CC)). The cumulative credibility of evidence is “strong”, with three 
“A” grades for the amount and replication of data and the protection from bias. The 
consensus per-allele OR is 1.39 (95% CI: 1.33–1.46). If those individuals with no risk 
alleles were used as the referent category, then TCF7L2 heterozygous individuals would be 
assigned an OR of 1.39. Those with two risk alleles would have an OR of 1.93 (1.39*1.39). 
In the row summarizing results of the HHEX gene marker, several meta-analyses pointed out 
the strong association between study sample size and moderate effect size (smaller studies 
having larger effects), but no attempt was made to grade or account for the potential of 
publication bias due to the finding of high heterogeneity (replication grade of “C”). A more 
detailed description of the literature search, how the risk allele frequencies were defined, 
included studies, tests of heterogeneity, and evaluation of publication bias for each of the 
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combinations listed in Table 2 are all included in Supplementary Appendix B online. 
Among the eight commonly tested genes evaluated by the Venice criteria, two had strong 
credibility (TCF7L2 and CDKN2A), two (CDKAL1 and PPARG) were graded as moderate, 
and four (HHEX, SLC308A, WFS1, and KCNJ11) were graded as having weak credibility. 
The per-allele OR ranged from 0.86 to 1.39. In one instance (PPARG), the risk allele 
frequency is >50%, indicating that the “risk” allele is actually protective and associated with 
reduced, rather than increased, risk for T2D.
Among the 19 additional markers included in Table 2 that were also included on a genomic 
panel, the per-allele ORs ranged from 1.06 to 1.18. Five of these 19 markers had no OR 
reported, as no published information was found in any search of PubMed or HuGE 
Navigator. Among the final eight markers identified through GWA studies, the per-allele 
ORs ranged from 1.04 to 1.15.
Clinical scenario 1: cumulative effect of multiple genomic markers and T2D—
To estimate a reasonable upper limit to the effect size that all of these genes might have on 
T2D risk in a general population, we defined a cumulative OR under the assumption that 
each genomic marker in Table 2 provides independent information about the risk for T2D 
and that none of the effects are synergistic. Three Monte Carlo models were created. The 
first combined only the four markers, TCF7L2, CDKN2A, CDKAL1, and PPARG, with the 
highest Venice grades and (ORs = 1.39, 1.22, 1.22, and 0.86, respectively) with highest 
credible evidence (Venice grades = strong or moderate). Figure 2a shows the overlapping 
distributions for the simulated cumulative OR for individuals with (open circles, dashed 
line) and without (filled circles, solid line) T2D. Using a cumulative OR of 1.38 as a cutoff 
(the demarcation between the 12th and 13th of the 20 intervals), 7.2% of T2D and 4.5% of 
normal individuals received cumulative ORs at or above this level. This interval was chosen 
under the assumption that any screening test identifying a “high-risk” population would 
likely have a relatively low false-positive rate of approximately 5–10%. A second model 
used the first eight makers (Table 2) for which a structured review was performed (Figure 
2b). Even though four more markers were added, the impact on performance is small, with a 
detection and false-positive rate of 7.8% and 4.9%, respectively (using the same 1.38 OR as 
a cutoff). Finally, a third model used all 30 markers (Table 2) that had an OR identified 
(Figure 2c). The effect of adding 23 more markers is to spread out the two distributions, but 
little improvement in performance is seen (detection and false-positive rates of 6.3% and 
3.4%, respectively). Figure 3 shows the relevant receiver-operating characteristic curves for 
all three models. The curves are similar, with areas under the curve of 0.547, 0.551, and 
0.570, respectively. A recently published simulation study39 concluded that improvements 
in net reclassification without an increase in the AUC are unlikely to result in a clinically 
useful improvement in performance. Even though more associations between genomic 
markers and T2D are reported almost monthly, the ORs are always low, and their addition to 
an existing panel will be minimal. In addition, the assumption of independence of markers 
would be less plausible, when the number of markers grows too large.
Clinical scenario 2: association of TCF7L2 with T2D in high-risk populations—
No published meta-analyses were identified that systematically reviewed the literature 
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regarding genotyping individuals at high risk of T2D for TCF7L2, and using the results to 
predict the probability of developing T2D within 4 or 5 years. No recent studies were 
identified as part of our update. For the rs7903146 SNP, two studies (in white, northern 
European populations) were included for the TT versus CC comparison.3,40 Summary 
measures were calculated using individual studies of TCF7L2 in high-risk populations. The 
overall OR was 1.66 (95% CI: 1.22–2.27; P = 0.001) for TT versus CC. For CT versus CC, 
the OR was 1.12 (95% CI: 0.85–1.48; P = 0.4). There was no evidence of heterogeneity (I2 
= 0%) for the former, and moderate heterogeneity for the latter (I2 = 25%). However, 
evidence for heterogeneity is limited because only two studies were pooled. Neither of the 
studies reported on >500 cases.
Four studies examined the predicted risk of developing T2D using TCF7L2 in combination 
with other markers,41–44 many of which were included in the review of clinical scenario 1. 
Because of the expanded panel, they are not directly relevant, but review of these results 
might provide indirect evidence for clinical validity in this setting. Each of the studies was 
in a similar high-risk population setting, and all used nongenetic factors in estimating risk. 
The net reclassification index (NRI)45 was used to determine the improvement of risk 
classification gained by including the results of genomic panel testing in addition to 
traditional risk factors. The NRI is most informative if the reclassification is first reported 
separately for both the cases (a positive percentage indicates improved risk classification 
among individuals who developed T2D) and the controls (a negative percentage indicates 
improved risk classification among individuals who did not develop T2D). The difference of 
these (NRIcase − NRIcontrol) is the overall NRI. Overall, the data from these four studies 
provide moderate evidence of little or no improvement in reclassification of risk, even if 
TCF7L2 were the main reason for any improvement:
• In 2008, Meigs et al.43 reported a prospective cohort study of 2,377 adults in which 
255 developed T2D within 28 years. A panel of 20 SNPs (including TCF7L2) was 
used to retrospectively genotype stored samples. The case, control, and total NRI 
were 1.2%, −1.1%, and 2.1%, respectively (P = 0.17).
• In 2010, Talmud et al.42 reported a prospective cohort study of 5,535 adults in 
which 302 developed T2D within 5 years. A panel of eight SNPs (including 
TCF7L2) was run on stored samples. The case, control, and total NRI were 6.4%, 
2.6%, and 3.8%, respectively (P = 0.24).
• In 2008, Lyssenko et al.41 reported on two prospective cohorts: 16,000 from 
Sweden and 3,000 from Finland. Over the next 23 years, 2,201 developed T2D. A 
panel of 11 SNPs (including TCF7L2) was tested on stored sera. The case, control, 
and total NRI were 2.6%, −1.9%, and 4.5%, respectively (P < 0.001).
• In 2010, De Miguel-Yanes et al.44 updated the information regarding the cohort 
published in 2008.43 There were now 446 individuals with T2D, and the panel was 
increased to 40 SNPs. Only the total NRI of 1.9% was reported (P = 0.2).
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A total of 79 studies were identified using our search strategy to evaluate clinical utility. 
After reviewing abstracts and full-text publications, three studies met inclusion criteria. Two 
randomized controlled trials3,9 and one prospective cohort8 reported intermediate and 
clinical outcomes for gene–intervention interaction ranging between 10 weeks and 7 years 
of follow-up. Patient populations included both those at high risk (impaired glucose 
tolerance and/or body mass index >30) as well as individuals from the general population. 
Data from these three studies were abstracted into evidence tables including genetic variant, 
population studied, outcome measured, and treatment effects stratified by genetic variant 
and intervention (Table 3).
Clinical scenario 1: cumulative effect of multiple genomic markers and T2D—
The EPIC-Potsdam study8 was a prospective case–cohort design with 773 individuals with 
T2D and 2,225 randomly selected population-based controls followed for an average of 7.1 
years (Table 3). The risk of developing T2D was associated with the TCF7L2 T allele 
(hazard ratio: 1.51) and was compared with daily consumption of whole grains stratified by 
TCF7L2 genotype. This observational study found a protective effect of whole-grain intake 
on diabetes risk exclusively applied to the CC genotype (hazard ratio relative to overall 
effect of 0.86 per 50 g/day), whereas those carrying at least one T allele showed no such 
benefit (hazard ratio relative to overall effect of 1.08 per 50 g/day).
Clinical scenario 2: association of TCF7L2 with T2D in high-risk populations—
The Diabetes Prevention Program3 was a multicenter randomized controlled trial comparing 
the effects of metformin and intensive lifestyle intervention aimed at reducing the incidence 
of T2D among obese individuals who already had impaired glucose tolerance testing results. 
Treatment with metformin was initiated at 850 mg administered orally once daily and raised 
to twice daily after the first month. The goal of the lifestyle intervention was to reduce body 
weight by 7% through a low-fat, low-carbohydrate diet with an average of 150 min of 
exercise per week. TCF7L2 genotyping was retrospectively performed on 3,549 patients 
(average age: 53.7 years and average body mass index: 34 kg/m2). The expectation was that 
in the placebo arm, the TT (at risk) population would have a higher incidence of T2D. At the 
end of an average of 3 years of follow-up, there was a 24% reduction in incident T2D in the 
metformin treatment arm and a 53% reduction in the lifestyle intervention arm as compared 
with placebo (hazard ratio: 1.81) in the at-risk (TT) population (row 2, Table 3). None of the 
interactions of genotype and intervention were significantly different from the placebo 
group.
The NUGENOB study9 was a multicenter randomized open-label trial that compared the 
benefits of two dietary interventions8 with intermediate outcomes relevant to T2D. Only the 
surrogate outcome of plasma fasting glucose is relevant to this review. Subjects ranged 
between the ages of 20 and 50 years with a body mass index of 30 kg/m2 or greater. A low-
fat diet (20–25% of energy from fat) was compared with a high-fat diet (40–45% from fat). 
The change in fasting plasma glucose was measured at baseline and at the end of a 10-week 
intervention period. The impact of the high- and low-fat diets was not associated with 
TCF7L2 genotype (row 3, Table 3).
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Recent studies have shown the effectiveness of bariatric surgery in reducing 
or reversing the negative effects of T2D—In a recent meta-analysis of 35 studies 
reporting laparoscopic adjustable gastric banding,46 weight loss over the first 2 years 
averaged 47%, whereas remission or improvement in diabetes varied from 53% to 70%. 
However, the studies were generally of low quality. Only one study was identified that 
evaluated TCF7L2 genotype among individuals undergoing bariatric surgery.47 Although 
these studies were performed in patients with T2D, the procedure would likely reduce the 
risk of developing T2D. They performed mRNA expression analysis on mRNA isolated 
from liver and found that TCF7L2 expression was unrelated to age or glycated hemoglobin 
but was associated with body mass index, depending on whether the obese patient had an 
existing diagnosis of T2D. It should be noted that TCF7L2 has a complex transcription and 
splicing pattern that varies between tissues, so analyses that do not distinguish between 
transcripts may obscure important differences.
Update on the availability and content of genomic panels for T2D—This targeted 
review addresses only those genes included on genomic profiles aimed at T2D that were 
available when the study was undertaken in mid-2010. Because it is possible that additional 
or updated panels may now exist, we repeated our search strategy in August 2011 and April 
2012. Two of the genomic panels in Table 2 have updated their panels. DecodeMe has 
added nine variants to its panel, and 23andMe has added two variants to its panel. Two new 
GWA studies were identified with new associated SNPs,25,26 none of these were associated 
with ORs >1.15. No new genomic panels for T2D risk were identified.
DISCUSSION
Quality of evidence
Analytic validity—The quality of evidence for analytic validity is inadequate (scale: 
inadequate, adequate, and convincing). For the panels/test described in Table 2, no 
publications were identified that provided relevant information on the analytic validity of 
testing for these gene variants. For many of the panels, the testing platform was not 
specified.
Clinical validity—The setting for clinical scenario 1 (Figure 1) was the general 
population, with testing of genetic variants to identify individuals at risk for T2D. The 
quality of evidence for clinical validity for clinical scenario 1 varied widely among the 27 
genes/variants identified on one or more of the T2D panels. The Venice grades ranged from 
strong to weak among the eight variants commonly found (Table 2). The strongest evidence 
was for the rs7903146 SNP in the TCF7L2 gene, with a per-allele OR of 1.39. We identified 
no information for four of the variants. Horizon scanning for relevant GWA studies results 
identified an additional eight potentially useful variants, but the per-allele ORs were all 1.15 
or smaller. In an attempt to quantify the potential for this type of testing to provide useful 
information, we created a model system under the assumption that the per-allele ORs for 
each of the reported variants provide independent information regarding the risk of 
developing T2D. Using a combination of the four most widely offered variants, the 
estimated AUC was 0.547. By adding an additional four, or including all 27 quantified 
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variants to the model, the AUC improved slightly to 0.551 and 0.570, respectively. Even if 
these test panel results are independent of traditional risk factors for T2D, they are in the 
range of AUCs considered unlikely to provide important clinically relevant improvements to 
T2D risk classification in the general population.48 Our modeling might have overestimated 
the combined effect if some markers are related (e.g., in the same biological pathway). 
Alternatively, if some markers interact to provide effect sizes that are larger than the product 
of the two, our model would underestimate the effect size. Therefore, the results of modeling 
the effect size for T2D or other genomic panels should only be considered an estimate.
The setting for clinical scenario 2 was a high-risk population (defined by obesity, impaired 
glucose tolerance, or both), with testing of a single genetic variant (the rs7903146 SNP in 
the TCF7L2 gene) to identify those individuals who will develop T2D. Two studies reported 
directly relevant data, with overall OR of 1.66 for the comparison of TT versus CC and 1.12 
for the CT versus CC comparison. These limited data are consistent with the 1.38 per-allele 
OR for this variant in the general population. Four other studies used the same TCF7L2 
variant in a genomic panel with other T2D-related variants to explore the reclassification of 
high-risk individuals and found little, if any, improvement. Overall, there is moderate 
evidence of, at most, minor improvement in risk classification using TCF7L2 genotyping in 
a population already at high risk of T2D.
Clinical utility—Two studies provided limited data on genotype-related differences in 
interventions aimed at reducing the risk of developing T2D in a general adult population 
(Table 3). Both restricted genotyping to TCF7L2 and both confirmed the higher risk 
associated with the high-risk homozygous genotype (Table 3). One of the studies examined 
the dietary intake of whole grains and found that individuals with at least one T allele did 
not benefit, whereas those without a T allele showed some reduction in risk, but the 
difference was not significant. Another report focused on the use of metformin and on 
lifestyle changes. None were found to interact with the TCF7L2 genotype. One study 
addressed a dietary intervention in the high-risk population and found no significant 
association with genotype and the change in fasting glucose. Overall, the quality of evidence 
for clinical utility in both scenarios is considered insufficient due to limited studies, limited 
interventions, and small sample sizes.
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• Little or no available information on the analytic validity of T2D panels, either 
in the published literature, or on the company websites. Often, it was not 
possible to even determine the testing platform or methodology being used.
• Which of the gene/variant associations identified might benefit from further 
localization of the causative variant to improve their credibility and effect size.
• Which, if any, of the gene/disease associations identified with moderate or weak 
credibility might be overestimated due to potential biases (e.g., publication 
bias).
• How multiple genomic markers for T2D should be combined and the types of 
data needed to inform these models.
• How genetic background/ethnicity would influence the OR for any particular 
variant.
• Alternative strategies for the prevention of T2D and how genomic markers 
might impact these strategies.
• Clinical trials to inform individuals with specific genotypes (e.g., TCF7L2) and 
how behavioral (i.e., diet and exercise) and/or pharmacological (i.e., metformin) 
changes effective T2D risk in the general or high-risk populations.
• How genomic markers for T2D can be incorporated into risk algorithms that 
include family history and whether genomic markers provide useful risk 
predication when family history is lacking (i.e., adoption cases).
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Laboratories performing analytic validation studies for T2D or other genomic panels 
should consider publishing their detailed results in peer-reviewed journals, as a way to 
build the evidence base for reliable testing. A consensus method should be developed to 
handle data with poor credibility and/or the existence of possible bias that could have a 
nontrivial impact on the effect size. This would allow more consistent and reliable 
modeling to occur. Further work on standardizing genotype models, summarizing/
evaluating the literature, combinations of genomic markers, and combinations of 
genomic and nongenomic markers should be continued.21,49
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Figure 1. Analytic frameworks
(a) Clinical scenario 1 shows the use of a multigene panel to estimate lifetime risk of 
developing type 2 diabetes (T2D) and improve patient outcomes. (b) Clinical scenario 2 
shows the use of TCF7L2 testing in a high-risk population to determine short-term (3–4 
year) risk of developing T2D and improve outcomes. The numbers correspond to the key 
questions contained in Table 1.
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Figure 2. Cumulative odds ratios (ORs) for 4, 8, and 30 genomic markers to predict type 2 
diabetes (T2D)
(a) The x-axis shows the cumulative OR for the four genomic markers with the most 
credible evidence (TCF7L2, CDKAL1, CDKN2A/B, and PPARG) in a simulated population 
of individuals developing T2D (dashed line with open circles) and a corresponding 
population of individuals who do not develop T2D (solid line with filled circles). Details of 
the model are described in the methods. Each circle represents the number of individuals per 
1,000 in each of the 20 intervals (equally spaced on the log scale) from cumulative ORs 
from 0.1 to 10. There is considerable overlap with the two groups, indicating poor test 
performance (false-positive rate: 4.5% and detection rate: 7.2%). (b) Includes the same 
information for the same four genomic markers along with the four next most commonly 
used markers (HHEX, SLC30A8, KCNJ11, and WFS1). Performance does not improve 
appreciably. (c) Includes all 30 genomic markers identified in the evidence review and 
results in the best, but still poor, performance. DR, detection rate; FPR, false-positive rate.
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Figure 3. A receiver-operating characteristic curve for three models of type 2 diabetes risk 
assignment based on genotyping specific sNPs
The detection rate (vertical axis) is plotted versus the false-positive rate (horizontal axis) for 
4, 8, and 30 genomic markers associated with type 2 diabetes. The dashed line indicates a 
“useless” test in which the false-positive rate and detection rate are equal. The four-marker 
model (open squares) has an area under the curve (AUC) of 0.547 and includes the strongest 
markers with the highest credibility (Table 2). The eight-marker model (open crossed 
diamonds) improved AUC to 0.551, by adding four more widely used markers. The 30-
marker model includes all markers on identified panels, along with additional markers 
identified through the examination of genome-wide association studies. The AUC increases 
to 0.570.
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Table 1
Key questions related to the analytic framework for both clinical scenarios
Clinical scenario 1: general population
1 Does the use of the T2D Multigene Panel test(s) lead to improved outcomes for the patient/consumer, or is it useful in medical or 
personal decision making? (overarching question)
2 What is known about the analytic validity of the test(s) used to identify the variations in the genes in the T2D Multigene Panel, 
including the analytic sensitivity and specificity, reproducibility, assay robustness (e.g., failure rates, resistance to changes in 
variables such as sample quality), and other factors?
3 What is the clinical validity of the T2D Multigene Panel, including clinical sensitivity and specificity and positive and negative 
predictive values?
a. What is the strength of association of the variants in these specific genes with risk for T2D (e.g., odds ratios)?
b. How well does this testing alone predict risk for T2D?
c. How well does this testing in combination with other clinical factors (e.g., family history, age, BMI/obesity, and glucose 
levels) predict risk for T2D?
d. How do other genetic and environmental factors (e.g., race/ethnicity, family history, smoking, diet, exercise level, and 
other conditions) affect the clinical validity of this test?
4 What are the issues related to the use of the T2D Multigene Panel test in the general population and its impact on patient/consumer 
outcomes?
a. What are the current management options for patients/consumers at risk for T2D based on a positive T2D Multigene Panel 
result in a medical model? How would recommendations differ from routine health messages? How would outcomes 
change based on use of this test in a direct-to-consumer model?
b. How could the results of the T2D Multigene Panel for risk of T2D in the general population impact health behaviors or 
inform decision making by patients and their health-care providers that affect outcomes?
c. In what ways could the use of the T2D Multigene Panel in the general population impact clinical outcomes (e.g., 
morbidity/mortality)?
d. What is known about other contextual issues, such as cost-effectiveness, likelihood of behavioral change, and family 
history considerations?
5 What are the potential harms associated with use of the T2D Multigene Panel (e.g., marketing direct to consumers, distress or 
stigma for a “poor prognosis” result, misinterpretation of results leading to excessive or inadequate treatment, exploitation of hyper-
vigilant people)?
Clinical scenario 2: high-risk population
1 Does the use of TCF7L2 testing lead to improved outcomes for the high-riska patient/consumer, or is it useful in medical or 
personal decision making? (overarching question)
2 What is known about the analytic validity of the test(s) used to identify the variation in the TCF7L2 gene, including the analytic 
sensitivity and specificity, reproducibility, assay robustness (e.g., failure rates, resistance to changes in variables such as sample 
quality), and other factors?
3 What is the clinical validity of TCF7L2 testing, including clinical sensitivity and specificity and positive and negative predictive 
values?
e What is the strength of association of the variant in this specific gene with short-term risk for T2D (e.g., odds ratios)?
f How well does this testing alone predict risk for T2D?
g How well does this testing in combination with other clinical factors (e.g., family history, age, BMI/obesity, and glucose 
levels) predict risk for T2D?
h How do other genetic and environmental factors (e.g., race/ethnicity, family history, smoking, diet, exercise level, and 
other conditions) affect the clinical validity of this test?
4 What are the issues related to the use of TCF7L2 testing in this high-risk population and its impact on patient/consumer outcomes?
a. What are the current management options for high-risk patients/consumers who have a positive TCF7L2 test result in the 
usual medical model? Would recommendations differ from routine health messages? How might the outcomes change in a 
direct to consumer model?
b. How could the results of TCF7L2 testing for risk of T2D in this high-risk population impact health behaviors or inform 
decision making by patients and their health-care providers that affect outcomes?
c. In what ways could the use of TCF7L2 testing in this high-risk population impact clinical outcome (e.g., morbidity/
mortality)?
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d. What is known about other contextual issues, such as cost-effectiveness, likelihood of behavioral change, and family 
history considerations?
5 What are the potential harms associated with TCF7L2 testing (e.g., marketing direct to consumers, distress or stigma for a “poor 
prognosis” result, misinterpretation of results leading to excessive or inadequate treatment, and exploitation of hypervigilant 
people)?
a
For example: overweight/obese (BMI ≥25 kg/m2) [wt (lbs)/height (in)2] × 703.0696] patients with impaired fasting glucose (IFG) or (IGT). IFG 
is defined as fasting plasma glucose 100 mg/dl (5.6 mmol/l) to 125 mg/dl (6.9 mmol/l). Impaired glucose tolerance (IGT) = 2-h plasma glucose 140 
mg/dl (7.8 mmol/l) to 199 mg/dl (11.0 mmol/l) as defined by the American Diabetes Association Standards of Medical Care in Diabetes—2012.19
BMI, body mass index; T2D, type 2 diabetes.
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